Gabrielle Lakusta

Gabrielle grew up in the Lower Mainland of B.C. and has lived in Vancouver since 2011. She holds an Associate of Arts Degree from Langara College, and a Bachelors of Arts Major in Journalism from Kwantlen Polytechnic University. Now, she writes for INN focusing on Life Science Investing. Aside from work, Gabrielle enjoys travelling, and enjoying the outdoors—especially when hiking and cycling.

glakusta@resourceinvestingnews.com

Articles

ImpediMed Announces First Patient Enrolled at Scripps Memorial Hospital

ImpediMed (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance...

October 15th, 2018

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101

Aimmune Therapeutics (Nasdaq:AIMT) a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2...

October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3

Arrowhead Pharmaceuticals (NASDAQ:ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial...

October 15th, 2018

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA),...

October 15th, 2018

NeoTract Announces Data from New Real-World Study

NeoTract, a wholly owned subsidiary of Teleflex (NYSE:TFX) focused on addressing unmet needs in the field of urology, announced the...

October 15th, 2018

Equillium Announces Pricing of Initial Public Offering

Equillium (Nasdaq:EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders...

October 12th, 2018

Alliqua BioMedical and Adynxx Announce Merger Agreement

Alliqua BioMedical (Nasdaq:ALQA) and Adynxx a privately held biopharmaceutical company, today announced that they have entered into a definitive merger...

October 12th, 2018